iiinova — where your digital self keeps evolving

Millie Hoe Science Journalist

@milliehoe.bsky.social

43 followers 26 following 74 posts

Scientific reporter with specific focus on biomanufacturing, biological sciences, cell and gene therapies and large molecules. Reporter for BioProcess Insider and BioXconomy.

Posts Replies Media

Millie Hoe Science Journalist @milliehoe.bsky.social · 29/05/2026

A startup biotech company out of King’s College London, Korecyte Bio, is using hypoxia to target solid tumors. It's agreement with CGT Catapult will focus on advancing its 'HypoxiCAR' platform for solid tumors. Read full article here: #kingscollege #CART www.bioprocessintl.com/deal-making/...

bioprocessintl.com

CGT Catapult teams with Korecyte Bio on low-oxygen CAR-T platform

A startup biotech company out of King’s College London is using hypoxia to target solid tumors.

Millie Hoe Science Journalist @milliehoe.bsky.social · 29/05/2026

UK’s NICE approves reimbursement of Genmab’s cervical cancer antibody drug. The regulatory body changed its opinion on antibody conjugate therapy Tivdak, paving the way for NHS use. Full article below: #NICE #cervicalcancer www.bioxconomy.com/modalities/u...

UK's NICE approves reimbursement of cervical cancer antibody drug

The regulatory body changed its opinion on antibody conjugate therapy Tivdak, paving way for NHS use.

Millie Hoe Science Journalist @milliehoe.bsky.social · 29/05/2026

Antibody developers are seeing regulatory wins and clinical trial successes for several different forms of cancer. From trial successes and approvals, antibodies are achieving better results than thought possible. Read my full article here: #antibodies #cancer www.bioxconomy.com/modalities/a...

Antibody earthquake immunotherapies reach cancer patients

Antibody drug developers are seeing regulatory wins and clinical trial successes for several different forms of cancer.

Millie Hoe Science Journalist @milliehoe.bsky.social · 29/05/2026

Capsida confirms the closure of the SYNRGY trial, with the safety of its gene therapy remaining unknown. The clinical trial for the rare disease STXBP1 was originally put on hold following the death of a child. Read my full article here: #clinicaltrial #capsida www.bioxconomy.com/modalities/c...

Capsida confirms closure of SYNRGY gene therapy trial

The clinical trial for the rare disease STXBP1 was originally put on hold following the death of a child.

Millie Hoe Science Journalist @milliehoe.bsky.social · 29/05/2026

Americans spend more on healthcare than any other country for worse outcomes. To help reduce the $4.8 trillion spent annually, companies like SHARx are sourcing prescriptions outside of the insurance system. Read my full article here: #drugprices #US www.bioprocessintl.com/bioprocess-i...

bioprocessintl.com

Rising drug costs challenge US healthcare system

Americans face soaring drug prices as PBMs inflate costs and rebates drive profits in a complex healthcare market.

000

Reposted by Millie Hoe Science Journalist

Søren Hough @sorenhough.bsky.social · 17/05/2026

This is such an impressive investigative piece from @milliehoe.bsky.social. It was an honor to get the chance to edit it alongside Josh Abbott. If you haven't given it a read, set aside a few minutes and check it out! Promise it's worth it.

Millie Hoe Science Journalist @milliehoe.bsky.social · 15/05/2026

The University of Barcelona is building a not-for-profit manufacturing model to get CAR Ts to patients sooner. Read my full article below: #nonprofit #CART #barcelona www.bioprocessintl.com/therapeutic-...

bioprocessintl.com

University of Barcelona tackles CAR-T therapy accessibility

University of Barcelona develops ARI-0001, a not-for-profit CAR-T therapy using EU hospital exemption rules to improve patient access to cancer treatment.

Millie Hoe Science Journalist @milliehoe.bsky.social · 13/05/2026

Large nonprofit The Gates Foundation is focusing on improving global health inequality by investing in biomanufacturing. Read my full article below: #nonprofit #gatesfoundation www.bioprocessintl.com/global-marke...

bioprocessintl.com

Gates Foundation invests in manufacturing to increase drug access

The large nonprofit is focusing on improving global health inequality by investing in biomanufacturing.

000

Millie Hoe Science Journalist @milliehoe.bsky.social · 12/05/2026

CEPI is using AI to achieve its vaccine goal, aiming to develop safe, effective vaccines within 100 days of identifying pandemic threats. Read my full article below: #AI #pandemic www.bioprocessintl.com/therapeutic-...

bioprocessintl.com

CEPI’s Pandemic Preparedness engine uses AI to predict outbreaks

CEPI uses AI to achieve its vaccine goal, aiming to develop safe, effective vaccines within 100 days of identifying pandemic threats.

000

Millie Hoe Science Journalist @milliehoe.bsky.social · 12/05/2026

Experimental DIY peptides are taking the US by storm. BioXconomy and BPI investigate the booming underground peptide market - and the dangers it brings with it. Read my full investigative piece below: #peptide #glp #investigation www.bioxconomy.com/modalities/d...

Experimental injectable peptides craze takes US by storm

BioXconomy and BPI investigate the booming underground peptide market – and the dangers it brings with it.

Millie Hoe Science Journalist @milliehoe.bsky.social · 12/05/2026

Lipid nanoparticles have transformed the way biologics are delivered, creating robust and highly specific treatment options across a range of conditions. Read my roundup on LNPs below: #LNPs #mRNA www.bioxconomy.com/modalities/l...

LNP versatility: From scarless healing to pancreatic cancer

Lipid nanoparticles have transformed the way biologics are delivered, creating robust and highly specific treatment options across a range of conditions.

Millie Hoe Science Journalist @milliehoe.bsky.social · 12/05/2026

New clinical trial results show promise for a monoclonal antibody immunosuppressant, allowing pancreatic islet transplants in diabetes patients. Read my full article below: #diabetes #transplant #antibodies www.bioxconomy.com/modalities/m...

mAb-based immunosuppressant supports diabetes cell transplants

New clinical trial results show promise for a monoclonal antibody immunosuppressant.

Millie Hoe Science Journalist @milliehoe.bsky.social · 12/05/2026

Boehringer Ingelheim are set to partner with OpenProtein.AI The collaboration will focus on the co-development of an AI antibody discovery platform. Read my full article below: #AI #antibody www.bioxconomy.com/modalities/p...

Boehringer Ingelheim partners with OpenProtein.AI

The collaboration will focus on the co-development of an AI antibody discovery platform.

Millie Hoe Science Journalist @milliehoe.bsky.social · 12/05/2026

Pharma giant GSK says it has seen positive results from its BEHOLD-1 trial treating ovarian and endometrial cancer. Read my full article below: #gsk #oncology www.bioxconomy.com/modalities/g...

GSK’s ADC succeeds in treating advanced gynecological cancers

The pharma giant says it has seen positive results from its BEHOLD-1 trial treating ovarian and endometrial cancer.

Millie Hoe Science Journalist @milliehoe.bsky.social · 08/05/2026

The US Pharmacopeia highlights risks of Red Sea trade disruptions due to the ongoing conflict with Iran, impacting US drug supplies. 73% of flumazenil APIs and 48% of amoxicillin supplies are at risk. Read my full article here: #iran #war #drugshortage www.bioprocessintl.com/global-marke...

bioprocessintl.com

USP warns Red Sea blockades may cause US drug shortages

The US Pharmacopeia highlights risks of Red Sea trade disruptions, impacting US drug supplies, with 73% of flumazenil APIs and 48% of amoxicillin at risk.

000

Millie Hoe Science Journalist @milliehoe.bsky.social · 17/04/2026

The Iran war may incite drug shortages in the US. From the import of key pharmaceutical ingredients to the rising manufacturing costs of medicines, the war is causing far-reaching issues beyond the price of oil. Read my full article below: #iran #pharma www.bioprocessintl.com/global-marke...

bioprocessintl.com

Middle East conflict disrupts global pharmaceutical supply chains

Middle East conflict disrupts pharma supply chains, raising costs and risking shortages of key medicines globally.

000

Millie Hoe Science Journalist @milliehoe.bsky.social · 14/04/2026

Pancreatic cancer is a devastating disease, with high mortality rates due to late symptom onset. Scientists speculate immune evasion is the reason for its late discovery. A new mRNA therapy from UPenn offers a solution. Read my full article here: #cancer #mRNA www.bioxconomy.com/modalities/c...

mRNA therapy thwarts pancreatic tumor immune evasion

mRNA delivered in vivo by antibody-targeted LNPs disrupts the defenses and microenvironment of pancreatic tumors.

Millie Hoe Science Journalist @milliehoe.bsky.social · 08/04/2026

Earlier this month, US President Donald Trump signed into effect a series of trade tariffs to hit the pharmaceutical and biotech industry. Read my full article below: #trump #pharma #tariffs www.bioprocessintl.com/regulations/...

bioprocessintl.com

Trump imposes tariffs on pharma to boost US drug manufacturing

President Trump enacts tariffs on imported drugs to strengthen US manufacturing, sparking industry concerns over costs, supply chains, and patient access.

000

Millie Hoe Science Journalist @milliehoe.bsky.social · 07/04/2026

Up to 30% of women with endometriosis experience fertility problems, and current cytokine-based treatments come with risks. A new mRNA therapy out of John Hopkins has shown promising preclinical results. Read my full article below: #endometriosis #fertility #mRNA www.bioxconomy.com/modalities/i...

Improving parenthood chances with endometrium-targeted mRNA

Peptide-directed mRNA-LNP could treat reproductive disorders by thickening the uterine lining.

Millie Hoe Science Journalist @milliehoe.bsky.social · 07/04/2026

Lonza announced it has inked a deal with ImmuneOncia to produce a monoclonal antibody (mAb) therapy. The treatment will target refractory NK/T-cell lymphoma, a rare form of blood cancer. Read my full article below: #lymphoma #blood #antibody www.bioprocessintl.com/deal-making/...

bioprocessintl.com

Lonza to manufacture ImmuneOncia’s antibody for lymphoma

Lonza partners with ImmuneOncia to manufacture Danburstotug, a promising mAb therapy for rare NK/T-cell lymphoma, advancing to Phase III trials.

Millie Hoe Science Journalist @milliehoe.bsky.social · 31/03/2026

For years, mental health professionals have observed an association between poor diet and severe depression. A new food-derived peptide could take advantage of this gut-brain connection. Read my full article below: #depression #diet #mentalhealth www.bioxconomy.com/modalities/y...

Using a food-derived peptide to treat depression, dementia

Researchers from Kyoto, Japan, are advancing a drug that modulates the gut-brain axis with pro-cognitive effects across a range of indications.

Millie Hoe Science Journalist @milliehoe.bsky.social · 31/03/2026

Pfizer recently announced promising Phase II clinical trial results (NCT05995964) for its trispecific antibody product, tilrekimig, targeting eczema and other inflammatory conditions. Read my full article below: #eczema #antibody #pfizer www.bioxconomy.com/modalities/p...

Pfizer's trispecific antibody shows promise against eczema

The pharmaceutical giant announced its candidate, tilrekimig, significantly reduced eczema severity in clinical trials.

Millie Hoe Science Journalist @milliehoe.bsky.social · 31/03/2026

What happens to gene therapies that are proven to save lives, but that are not commercially viable? Academic institutions are picking up the slack in a for-profit industry. Read my full article below: #genetherapy #access #nonprofit www.bioprocessintl.com/upstream-dow...

bioprocessintl.com

Academic institutions tackle gene therapy costs and accessibility

Academics innovate gene therapy manufacturing to cut costs and improve access, addressing commercialization challenges and saving lives worldwide

Millie Hoe Science Journalist @milliehoe.bsky.social · 31/03/2026

The FDA asked pharma company UniQure for a “double-blind, sham surgery-controlled study” of its mutation-rescuing Huntington’s disease therapy. Study leader Edward Wild has expressed ethical concerns. Read my full article below: #FDA #Huntington #genetherapy www.bioxconomy.com/modalities/f...

FDA demands sham arm for Huntington’s gene therapy

The US agency’s U-turn would postpone treatment for participants in the placebo group.

Millie Hoe Science Journalist @milliehoe.bsky.social · 31/03/2026

Researchers from Columbia University were able to up-regulate a cardio-protective peptide in animal models using self-amplifying RNA. The peptide preserves cardiac function after a heart attack. Read my full article below: #heart #peptide #heartattack www.bioxconomy.com/modalities/h...

RNA-delivered peptide boosts recovery after heart attack

A self-amplifying RNA with a “smart drug activation system” provides heart tissue-specific regeneration.

Millie Hoe Science Journalist @milliehoe.bsky.social · 31/03/2026

CDMO Neuland Laboratories announced that it will open its peptide facility in summer 2026. The site, which will produce glucagon-like peptide-1 (GLP-1s), is just 40 miles from Hyderabad, India. Read my full article below: #peptide #GLP www.bioxconomy.com/modalities/n...

Neuland announces plans for Hyderabad GLP-1 CMC facility

Located in the village of Bonthapally, the peptide CMC site is set to open summer 2026.

Millie Hoe Science Journalist @milliehoe.bsky.social · 10/03/2026

‘Quieting craving itself’: GLP-1s reduce risk of substance addiction in US veterans In a landmark observational study of over 600,000 US veterans with type-2 diabetes, #GLPs reduced addiction rates and adverse outcomes. Read my full article below: #news #science www.bioxconomy.com/modalities/q...

GLP-1s reduce risk of substance addiction in US veterans

A study of over 600,000 veterans suggests GLP-1s reduce the chances of developing addiction while improving outcomes for those already addicted.

Millie Hoe Science Journalist @milliehoe.bsky.social · 10/03/2026

The South African government and Gilead Sciences enter discussions for local manufacturing of #HIV preventative drug, lenacapavir. The initiative is part of a scheme with Unitaid to increase equitable access in endemic areas. Read my full article below: #news www.bioprocessintl.com/bioprocess-i...

bioprocessintl.com

South Africa negotiate with Gilead for HIV drug

Gilead’s investigational drug lenacapavir provides protection against infection.

Millie Hoe Science Journalist @milliehoe.bsky.social · 10/03/2026

Peptides market to explode following success of GLP-1s. Experts predict a value of almost $300 billion by 2033, with the US dominating more than 60% of the market. #news #invest #glps Read my full article below: www.bioxconomy.com/modalities/p...

Peptide therapeutics market set to soar

The US is driving innovation in the peptide therapeutics space, especially around GLP-1s.

Millie Hoe Science Journalist @milliehoe.bsky.social · 10/03/2026

Merck make 150+ redundancies as HPV vaccine sales plummet. The company announced layoffs at its Durham, North Carolina facilities as Gardasil sales fail to meet expectations. Read my full article below: #news #merck #vaccine www.bioprocessintl.com/global-marke...

bioprocessintl.com

Merck identifies redundancies in NC as vaccine sales plummet

The company announced layoffs at its Durham facilities as Gardasil sales fail to meet expectations.

000

Millie Hoe Science Journalist @milliehoe.bsky.social · 10/03/2026

AAV-associated toxicity in gene therapies could be caused by contaminants in the manufacturing process, a research team based out of London claim. Liver biopsies tested positive for viral fragments. Read my full article below: #genetherapy #AAV #news www.bioprocessintl.com/therapeutic-...

bioprocessintl.com

Manufacturing contaminants linked with toxicity in gene therapies

A research team from London examined the relationship between adenovirus-associated virus (AAV)-based vectors and liver toxicity in gene therapy patients.

Millie Hoe Science Journalist @milliehoe.bsky.social · 03/03/2026

Monoclonal antibody cocktails show promise in combating RSV, reducing viral titers in studies. A new frontier in respiratory infection prevention. #RSV #AntibodyTherapy Read my full article below: www.bioxconomy.com/modalities/s...

Using monoclonal antibody cocktails to fight RSV

Researchers at two Chinese universities have shown that combination antibody therapies could prevent respiratory infections.

Millie Hoe Science Journalist @milliehoe.bsky.social · 27/02/2026

Cellipont Bioservices and Soter Bio team up to advance lipid nanoparticle manufacturing for RNA therapies, enhancing US-based GMP production and regulatory support. #Biotech #RNA Read the full article below: www.bioprocessintl.com/deal-making/...

bioprocessintl.com

Cellipont and Soter Bio team to manufacture lipid nanoparticles

The collaboration will focus on the production of delivery methods for complex cell therapies.

000

Millie Hoe Science Journalist @milliehoe.bsky.social · 26/02/2026

FDA fast-tracks a new framework for personalized therapies targeting ultra-rare diseases, paving the way for faster innovation and tailored treatments. A win for precision medicine #FDA #RareDiseases Read the full article below: www.bioprocessintl.com/regulations/...

bioprocessintl.com

FDA fast-tracks framework for rare-disease therapies

The initiative allows accelerated approval of curative therapies for ultra-rare conditions.

000

Millie Hoe Science Journalist @milliehoe.bsky.social · 26/02/2026

Yonsei University revolutionizes oligo synthesis with 3D-printed microcolumns, merging high throughput with accuracy for diverse DNA sequences. A breakthrough in precision and scalability #Biotech #Innovation Read the full article below: www.bioxconomy.com/modalities/b...

Oligo synthesis reinvented with 3D-printed microcolumns

Yonsei University researchers have combined the benefits of planar array platforms with those of column-based synthesis.

000

Millie Hoe Science Journalist @milliehoe.bsky.social · 24/02/2026

Axplora expands its Le Mans site to meet growing demand for ADCs, boosting manufacturing capacity and advancing innovation in targeted cancer therapies. #Biotech #ADC #Manufacturing Read my full article below: www.bioprocessintl.com/facilities-c...

bioprocessintl.com

Axplora expands Le Mans site to support increased ADC demand

Axplora invests $30 million in lyophilization at Le Mans site, boosting ADC production. Facilities enhance control, reliability, and traceability.

000

Millie Hoe Science Journalist @milliehoe.bsky.social · 24/02/2026

FDA reverses course on Moderna's mRNA flu vaccine, now under review after initial rejection. Approval could come by August. This marks another knock-on effect of RFK's vaccine hesitancy. #mRNA #FluVaccine Read the full article below: www.bioxconomy.com/modalities/f...

Moderna’s flu vaccine gets second shot after initial snub

The agency reversed its initial decision refusing to review the mRNA flu vaccine in a whirlwind week for the pharma company.

000

Millie Hoe Science Journalist @milliehoe.bsky.social · 20/02/2026

Andelyn Bio & Drake Rayden team up to develop AAVs targeting rare pediatric diseases. A promising collaboration for advancing gene therapy. #GeneTherapy #RareDiseases #Biotech Read below: www.bioprocessintl.com/deal-making/...

bioprocessintl.com

Andelyn Bio and Drake Rayden partner on rare disease treatment

The partnership will focus on the clinical grade manufacturing of AAVs.

000

Millie Hoe Science Journalist @milliehoe.bsky.social · 20/02/2026

Scientists are using caffeine as an "on-switch" for CRISPR, unlocking new precision in gene editing. A groundbreaking brew for biotech innovation☕ #CRISPR #Biotech #Innovation Read below: www.bioxconomy.com/modalities/t...

Thanks a latte: Using caffeine as an on switch for CRISPR

Texas A&M researchers have harnessed chemogenetics and nanobodies to control gene expression in cell culture, with an eye toward biomedical applications.

000

Millie Hoe Science Journalist @milliehoe.bsky.social · 20/02/2026

The FDA Rare Disease Fast Track Program reauthorization is a major win for small biotechs, offering financial lifelines for rare disease drug development. #RareDiseases #Biotech Read below: www.bioprocessintl.com/regulations/...

bioprocessintl.com

FDA fast-track program passes Senate in win for small biotechs

The milestone is being celebrated as a “huge moment” for rare disease drug development.

000

Millie Hoe Science Journalist @milliehoe.bsky.social · 16/02/2026

Novo Nordisk confirms Irish expansion to produce Wegovy® pills, meeting surging demand for obesity treatments. A key step in scaling global supply. #Pharma #Wegovy #Ireland #ObesityTreatment Read below: www.bioprocessintl.com/facilities-c...

bioprocessintl.com

Novo Nordisk expands Irish facility after Wegovy pill success

Novo Nordisk CEO announces Irish facility expansion after Wegovy pill success, despite competition from Eli Lilly and legal action against Hims & Hers.

000

Millie Hoe Science Journalist @milliehoe.bsky.social · 16/02/2026

Fujifilm opens a $540M UK expansion, uniting R&D, manufacturing, and quality control under one roof. This state-of-the-art site aims to streamline biopharma production and innovation. #Biopharma #Innovation #UKExpansion Read below: www.bioprocessintl.com/facilities-c...

bioprocessintl.com

Fujifilm Biotechnologies invests $540m in Teesside facility

Fujifilm Biotechnologies expands its Teesside facility with a £400 million investment to boost UK biomanufacturing.

000

Millie Hoe Science Journalist @milliehoe.bsky.social · 16/02/2026

PharmaEssentia invests $46M in Puerto Rico to establish a U.S. manufacturing hub for BESREMi®, boosting supply chain resilience and supporting global demand for its hematology therapy. Operations expected by 2027. #Biopharma #PuertoRico Read below: www.bioprocessintl.com/facilities-c...

bioprocessintl.com

PharmaEssentia to establish $46m Puerto Rican facility

PharmaEssentia invests $46 million in Puerto Rico to bolster BESREMi production and strengthen US supply chains.

000

Millie Hoe Science Journalist @milliehoe.bsky.social · 10/02/2026

Capsida Biotherapeutics confirms cerebral edema as the cause of death in its SYNRGY trial for STXBP1-related disorders. The trial remains paused as investigations continue. Patient safety is the priority. #GeneTherapy #ClinicalTrials Read my full article below: www.bioxconomy.com/modalities/c...

Capsida confirms cause of death in clinical trial fatality

The gene therapy company’s update offers some clarity, but experts still have questions.

000

Millie Hoe Science Journalist @milliehoe.bsky.social · 05/02/2026

AdvanCell and 48Hour Discovery team up to develop a ²¹²Pb-based peptide radiotherapeutic for gastrointestinal cancer, combining cutting-edge discovery and alpha therapy expertise. #Biotech #Innovation Read below: www.bioprocessintl.com/deal-making/...

bioprocessintl.com

AdvanCell and 48Hour Discovery partner on radiotherapeutics

The partnership will focus on a novel lead-based therapy for gastrointestinal cancer.

Millie Hoe Science Journalist @milliehoe.bsky.social · 04/02/2026

HanchorBio teams up with WuXi Biologics to accelerate the manufacturing of immuno-oncology fusion proteins. This partnership aims to streamline development timelines and advance innovative cancer therapies. #Biotech #ImmunoOncology Read below: www.bioprocessintl.com/deal-making/...

bioprocessintl.com

HanchorBio teams with WuXi to produce immuno-oncology proteins

The collaboration will focus on the advancement of HanchorBio’s oncology and autoimmune pipelines.

000

Millie Hoe Science Journalist @milliehoe.bsky.social · 03/02/2026

Cellares secures $600M in funding, including $257M in Series D, to scale automated smart factories globally. Aiming for clinical manufacturing in 2026 and commercial launch by 2027. #Biotech #CellTherapy Read below: www.bioprocessintl.com/facilities-c...

bioprocessintl.com

Cellares hits $600m milestone for automated smart factories

The latest round of series-D funding secured over $250 million for the construction of several sites.

000

Millie Hoe Science Journalist @milliehoe.bsky.social · 30/01/2026

An excellent piece of investigative journalism by our talented editors Joshua Abbott and Søren Hough. Opens an interesting conversation regarding the ethics of clinical trials conducted overseas, and the implications of anti-vaccination sentiments. Read below: www.bioxconomy.com/modalities/b...

A vaccine trial in Guinea-Bissau comes under intense scrutiny

An RFK, Jr.-linked vaccine trial in Guinea-Bissau is not cancelled, despite reports.

Millie Hoe Science Journalist @milliehoe.bsky.social · 29/01/2026

mRNA-antibody combo shows promise in keeping melanoma at bay🧬💉 A groundbreaking step in cancer treatment. Learn more: #CancerResearch #mRNA #Innovation www.bioxconomy.com/modalities/m...

mRNA-antibody combination treatment keeps melanoma at bay

Five-year interim data published by Moderna and Merck show a 49% reduction in melanoma recurrence and deaths.

000

Millie Hoe Science Journalist @milliehoe.bsky.social · 28/01/2026

SK Bioscience secures $30M partnership to enhance Ebola vaccine production! 💉🌍 A major step in global health innovation. Learn more: #Vaccines #Biotech #GlobalHealth www.bioprocessintl.com/therapeutic-...

bioprocessintl.com

SK biosciences secures $30m Ebola vaccine partnership

The firm announced its participation in a scheme to improve Ebola virus vaccine development.